Polio vaccination: Past, present and future

Future Microbiology

Volumn 10, Issue 5, 2015, Pages 791-808

  Bandyopadhyay, Ananda S ^a   Garon, Julie ^b   Seib, Katherine ^b   Orenstein, Walter A ^b  

^a BILL AND MELINDA GATES FOUNDATION   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

disease eradication; inactivated polio vaccine; polio end game; vaccine technology

Indexed keywords

ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; INACTIVATED VACCINE; LIVE VACCINE;

DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNITY; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRAL CLEARANCE; VIRUS TRANSMISSION; HISTORY; IMMUNOLOGY; PROCEDURES; TRENDS;

POLIOVIRUS;

HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; POLIOMYELITIS; POLIOVIRUS VACCINES; VACCINATION; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 84929736523     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.15.19     Document Type: Review

References (94)

1. The Global Polio Eradication Initiative. Data Monit. www.polioeradication.org
2. World Health Organization. Immunization schedules by antigens. Data Stat. Graph. http://apps.who.int/immunization
3. UNICEF. Current IPV supply, recent tender results & outlook for the future. (2012). www.unicef.org/supply/files/IPV-Supply
4. Aylward B, Tangermann R. The global polio eradication initiative: lessons learned and prospects for success. Vaccine 29(Suppl. 4), D80-D85 (2011).
5. Platt LR, Estívariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J. Infect. Dis. 210(Suppl. 1), S380-S389 (2014).
6. th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). W.B. Saunders, London, UK, 623-624 (2013).
7. Kohler KA, Banerjee K, Gary Hlady W, Andrus JK, Sutter RW. Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bull. World Health Organ. 80(3), 210-216 (2002).
8. Aylward B, Yamada T. The polio endgame. N. Engl. J. Med. 364(24), 2273-2275 (2011).
9. Global Polio Eradication Initiative. Polio eradication & endgame strategic plan 2013-2018 (2013). www.polioeradication.org/Portals
10. Resik S, Tejeda A, Sutter RW et al. Priming after a fractional dose of inactivated poliovirus vaccine. N. Engl. J. Med. 368(5), 416-424 (2013).
11. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev. Infect. Dis. 13(5), 926-939 (1991).
12. Sutter RW, Pallansch MA, Sawyer LA, Cochi SL, Hadler SC. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann. NY Acad. Sci. 754(1), 289-299 (1995).
13. Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 8(4), e1002599 (2012).
14. Sutter RW, John TJ, Jain H et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 376(9753), 1682-1688 (2010).
15. Estivariz CF, Pallansch MA, Anand A et al. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr. Opin. Virol. 3(3), 309-315 (2013).
16. Dayan GH, Thorley M, Yamamura Y et al. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J. Infect. Dis. 195(1), 12-20 (2007).
17. Plotkin SA. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17(7), 1055-1065 (2010).
18. th Edition). Vidor E, Stanley A (Eds). Plotkin Elsevier/Saunders, PA, USA, 573-597 (2013).
19. Laassri M, Lottenbach K, Belshe R et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J. Infect. Dis. 192(12), 2092-2098 (2005).
20. Anis E, Kopel E, Singer S et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveill. 18(38), pii: 20586 (2013).
21. Kopel E, Kaliner E, Grotto I. Lessons from a public health emergency - importation of wild Poliovirus to Israel. N. Engl. J. Med. 371(11), 981-983 (2014).
22. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 46(RR-3), 1-25 (1997).
23. Epidemiology and prevention of vaccine-preventable diseases (The Pink Book). In: Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe C, Hamborsky J (Eds). Centers for Disease Control and Prevention, GA, USA, 249-261 (2012).
24. Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr. Infect. J. 16(3), 312-322 (1997).
25. World Health Organization. Global Advisory Committee on Vaccine Safety, 11-12 December 2013. Wkly Epidemiol. Rec. 7(89), 53-60 (2014).
26. Maglione MA, Das L, Raaen L et al. Safety of vaccines used for routine immunization of US children: a systematic review. Pediatrics 134(2), 325-337 (2014).
27. Robertson SE, Traverso HP, Drucker JA et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet 1(8591), 897-899 (1988).
28. Moriniere BJ, Van Loon FPL, Rhodes PH et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet 341(8860), 1545-1550 (1993).
29. Estivariz CF, Jafari H, Sutter RW et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect. Dis. 12(2), 128-35 (2012).
30. John J, Giri S, Karthikeyan AS et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet 384(9953), 1505-1512 (2014).
31. Jafari H, Deshpande JM, Sutter RW et al. Efficacy of inactivated poliovirus vaccine in India. Science 345(6199), 922-925 (2014).
32. Meeting of the Strategic Advisory Group of Experts on immunization, November 2013 - conclusions and recommendations. Wkly Epidemiol. Rec. 89(1), 1-20 (2014).
33. Polio vaccines: WHO position paper, January 2014. Wkly Epidemiol. Rec. 89(9), 73-92 (2014).
34. Estívariz CF, Molnár Z, Venczel L et al. Paralytic poliomyelitis associated with Sabin monovalent and bivalent oral polio vaccines in Hungary. Am. J. Epidemiol. 174(3), 316-325 (2011).
35. Kapusinszky B, Molnar Z, Szomor KN, Berencsi G. Molecular characterization of poliovirus isolates from children who contracted vaccine-associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunol. Med. Microbiol. 58(2), 211-217 (2010).
36. Cáceres VM, Sutter RW. Sabin monovalent oral Polio vaccines: review of past experiences and their potential use after polio eradication. Clin. Infect. Dis. 33(4), 531-541 (2001).
37. Dömök I. Experiences associated with the use of live poliovirus vaccine in Hungary, 1959-1982. Rev. Infect. Dis. 6(Suppl. 2), S413-S418 (1984).
38. Alexander L, Seward JF, Santibanez TA et al. VAccine policy changes and epidemiology of poliomyelitis in the united states. JAMA 292(14), 1696-1701 (2004).
39. Modlin JF, Halsey NA, Thoms ML, Meschievitz CK, Patriarca PA. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. J. Infect. Dis. 175(Suppl. 1), S228-S234 (1997).
40. Asturias EJ, Dueger EL, Omer SB et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. J. Infect. Dis. 196(5), 692-698 (2007).
41. Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J. Infect. Dis. 162(6), 1291-1297 (1990).
42. Okayasu H, Sutter RW, Czerkinsky C, Ogra PL. Mucosal immunity and poliovirus vaccines: impact on wild poliovirus infection and transmission. Vaccine 29(46), 8205-8214 (2011).
43. Grassly NC, Jafari H, Bahl S et al. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. J. Infect. Dis. 200(5), 794-801 (2009).
44. Du Châtelet IP, Merchant AT, Fisher-Hoch S et al. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine 21(15), 1710-1718 (2003).
45. Anand A, Pallansch MA, Estivariz CF, Gary H, Wassilak SGF. Estimating the likely coverage of inactivated poliovirus vaccine in routine immunization: evidence from demographic and health surveys. J. Infect. Dis. 210(Suppl. 1), S465-S474 (2014).
46. Martin J. Consequences of the introduction of the new inactivated poliovirus vaccine into the Expanded Programme on Immunization. Rev. Infect. Dis. 6(Suppl. 2), S480-S482 (1984).
47. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM et al. Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal. 33(4), 606-646 (2013).
48. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM et al. Expert review on poliovirus immunity and transmission. Risk Anal. 33(4), 544-605 (2013).
49. Mangal TD, Aylward RB, Grassly NC. The potential impact of routine immunization with inactivated poliovirus vaccine on wild-type or vaccine-derived poliovirus outbreaks in a posteradication setting. Am. J. Epidemiol. 178(10), 1579-1587 (2013).
50. Wahjuhono G, Revolusiana, Widhiastuti D et al. Switch from oral to inactivated poliovirus vaccine in Yogyakarta Province, Indonesia: summary of coverage, immunity, and environmental surveillance. J. Infect. Dis. 210(Suppl. 1), S347-S352 (2014).
51. Immunogenicity of 1 or 2 doses of bOPV in Chilean infants primed with IPV vaccine. www.clinicaltrials.gov/ct2/show/NCT018416
52. Safety and immunogenicity of 1 or 2 doses of IPV in Latin American infants primed with bivalent OPV vaccine. www.clinicaltrials.gov/ct2/show/NCT018310
53. John J. Comparative evaluation of immunogenicity and reactogenicity of bivalent oral poliovirus vaccine (bOPV) and trivalent oral poliovirus vaccine (tOPV) in the standard EPI schedule, with or without inactivated polio vaccine (IPV) administration at DTP3 contact: A randomized controlled trial. CTRI/2013/06/003722. http://ctri.nic.in/Clinicaltrials
54. Immunogenicity of inactivated and live Polio vaccines. www.clinicaltrials.gov/ct2/show/NCT018136
55. John J. Duration of Intestinal immunity following inactivated poliovirus vaccine in OPV primed children. CTRI/2014/09/004979. http://ctri.nic.in/Clinicaltrials/showallp.php
56. IPV Clinical Trial - The Gambia. www.clinicaltrials.gov/ct2/show/NCT01847
57. Salk J, Cohen H, Fillastre C et al. Killed poliovirus antigen titration in humans. Dev. Biol. Stand. 41, 119-132 (1977).
58. Salk J, Van Wezel AL, Stoeckel P et al. Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis. Dev. Biol. Stand. 47, 181-198 (1980).
59. Salk J, Stoeckel P, Van Wezel AL, Lapinleimu K, Van Steenis G. Antigen content of inactivated poliovirus vaccine for use in a one-or two-dose regimen. Ann. Clin. Res. 14(5-6), 204-212 (1982).
60. World Health Organization. Report from WHO Expert Committee on Biological Standardization. http://whqlibdoc.who.int/trs/WHO
61. Safety study of a single dose of monovalent high-dose inactivated Poliovirus type 2 vaccine (m-IPV2 HD) in infants early in life. www.clinicaltrials.gov/ct2/show/NCT021111
62. Geert Leroux- Roels. Phase 1 Study on the safety and reactogenicity of a single dose of monovalent high-dose inactivated Poliovirus type 2 Vaccine (m-IPV2 HD) given intramuscularly compared to standard trivalent inactivated Poliovirus vaccine (IPV) in healthy adults. http://clinicaltrials.gov/show/NCT01997632
63. Verdijk P, Rots NY, van Oijen MGCT et al. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants. Vaccine 32(39), 4938-4944 (2014).
64. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr. Top. Microbiol. Immunol. 333, 369-393 (2009).
65. Engert J. Implants as sustained release delivery devices for vaccine antigens. In: Subunit Vaccine Delivery. Foged C, Rades T, Perrie Y, Hook S (Eds). Springer NY, USA, 221-241 (2015).
66. Schoellhammer CM, Blankschtein D, Langer R. Skin permeabilization for transdermal drug delivery: recent advances and future prospects. Expert Opin. Drug Deliv. 11(3), 393-407 (2014).
67. Macadam AJ, Ferguson G, Stone DM et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J. Virol. 80(17), 8653-8663 (2006).
68. Toyoda H, Yin J, Mueller S, Wimmer E, Cello J. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res. 67(6), 2857-2864 (2007).
69. Lauring AS, Jones JO, Andino R. Rationalizing the development of live attenuated virus vaccines. Nat. Biotechnol. 28(6), 573-579 (2010).
70. Burns CC, Campagnoli R, Shaw J, Vincent A, Jorba J, Kew O. Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons. J. Virol. 83(19), 9957-9969 (2009).
71. Burns CC, Shaw J, Campagnoli R et al. Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region. J. Virol. 80(7), 3259-3272 (2006).
72. Coleman JR, Papamichail D, Skiena S, Futcher B, Wimmer E, Mueller S. Virus attenuation by genome-scale changes in codon pair bias. Science 320(5884), 1784-1787 (2008).
73. De Jesus N, Franco D, Paul A, Wimmer E, Cello J. Mutation of a single conserved nucleotide between the cloverleaf and internal ribosome entry site attenuates poliovirus neurovirulence. J. Virol. 79(22), 14235-14243 (2005).
74. Vignuzzi M, Wendt E, Andino R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat. Med. 14(2), 154-161 (2008).
75. The polio pipeline - a quarterly update of ongoing research in the Global Polio Eradication Initiative. www.polioeradication.org/Portals
76. Heymann DL, Sutter RW, Aylward RB. A global call for new polio vaccines. Nature 434(7034), 699-700 (2005).
77. Hawken J, Troy SB. Adjuvants and inactivated polio vaccine: a systematic review. Vaccine 30(49), 6971-6979 (2012).
78. th Edition). Plotkin SA, Offit PA, Orenstein W (Eds). W.B. Saunders, London, UK, 58-70 (2013).
79. Ivanov AP, Dragunsky EM, Chumakov KM. 1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. J. Infect. Dis. 193(4), 598-600 (2006).
80. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 12(8), 592-605 (2012).
81. Summerton NA, Welch RW, Bondoc L et al. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 28(5), 1404-1411 (2010).
82. Nelson KS, Janssen JM, Troy SB, Maldonado Y. Intradermal fractional dose inactivated polio vaccine: a review of the literature. Vaccine 30(2), 121-125 (2012).
83. Nirmal S, Cherian T, Samuel BU, Rajasingh J, Raghupathy P, Jacob John T. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine 16(9), 928-931 (1998).
84. Simoes EF, Padmini B, Steinhoff MC, Jadhav M, John T. ANtibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. Am. J. Dis. Child. 139(10), 977-980 (1985).
85. Cadorna-Carlos J, Vidor E, Bonnet MC. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. Int. J. Infect. Dis. 16(2), e110-e116 (2012).
86. Mohammed AJ, AlAwaidy S, Bawikar S et al. Fractional doses of inactivated poliovirus vaccine in Oman. N. Engl. J. Med. 362(25), 2351-2359 (2010).
87. Resik S, Tejeda A, Lago PM et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J. Infect. Dis. 201(9), 1344-1352 (2010).
88. Lago PM, Cáceres VM, Galindo MA et al. Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: implications for stopping polio vaccination after global eradication. Int. J. Epidemiol. 30(5), 1029-1034 (2001).
89. Norman JJ, Arya JM, McClain MA, Frew PM, Meltzer MI, Prausnitz MR. Microneedle patches: usability and acceptability for self-vaccination against influenza. Vaccine 32(16), 1856-1862 (2014).
90. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 27(3), 454-459 (2009).
91. van der Maaden K, Trietsch SJ, Kraan H et al. Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination: a study with polio vaccine in rats. Pharm. Res. 31, 1846-1854 (2014).
92. Correia-Pinto JF, Csaba N, Alonso MJ. Vaccine delivery carriers: insights and future perspectives. Int. J. Pharm. 440(1), 27-38 (2013).
93. Bakker WA, Thomassen YE, van't Oever AG et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 29(41), 7188-7196 (2011).
94. Weekly Epidemiological Record. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2014 - conclusions and recommendations. World Health Organization. Wkly Epidemiol. Rec. 89(21), 221-236 (2014).